Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The primary objective is to maintain a permanent readiness posture and commercially sustainable warm-base production capacity for the rapid manufacture of vaccines, antigens, and adjuvants during public health emergencies. Selected contractors will be responsible for producing countermeasures against influenza and other viruses with pandemic potential, generating necessary analytical, nonclinical, clinical, and chemistry, manufacturing, and controls data for FDA submission, and preparing candidate vaccine viruses. To be eligible, offerors must demonstrate successful experience in influenza vaccine manufacturing, evidenced by holding a U.S. influenza vaccine license or having submitted a Biologics License Application to the FDA. The contract is structured as an IDIQ with a five-year base period and a five-year option, totaling a potential 120-month ordering period. Award decisions will be based on the Highest Technically Rated Offerors with a Fair and Reasonable Price methodology, with a critical requirement for offerors to achieve a High Confidence rating in capabilities. Key deliverables include the submission of comprehensive manufacturing and supply chain continuity plans, surge readiness assessments, and strict adherence to CGMP guidelines and ASPR security requirements. Performance is monitored through a BARDA dose tracker, and final acceptance is contingent upon the submission of final reports and verified temperature control documentation during delivery. Invoicing is conducted quarterly via the Department of Treasury Invoice Processing Platform.